Anti-TIGIT Domvanalimab Plus Zimberelimab Shows Over One Year Progression-Free Survival in Upper GI Cancer
Saturday, 1 June 2024, 09:12
Gilead and Arcus Announcement
The collaboration between Gilead and Arcus has produced promising results in the treatment of upper gastrointestinal (GI) cancers. The study focused on the combination of Anti-TIGIT Domvanalimab and Zimberelimab alongside chemotherapy.
One Year Progression-Free Survival
The key highlight of the study is the achievement of over one year in median progression-free survival for patients undergoing this first-line treatment. This outcome signifies a significant advancement in the field of oncology.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.